Gregg Gilbert
Stock Analyst at Truist Securities
(2.26)
# 2,723
Out of 5,127 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $15.06 | +12.88% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $46.74 | -20.84% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $60.86 | +38.02% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,025.00 | -48.78% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $4.45 | +192.13% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $10.47 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $117.15 | -20.61% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $26.88 | +78.57% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $2.11 | +1,132.23% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.64 | +23,484.91% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $14.39 | +442.04% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $128.13 | -39.12% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $34.37 | -47.63% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $187.02 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $165.63 | +5.66% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $222.44 | -70.33% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $15.06
Upside: +12.88%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $46.74
Upside: -20.84%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $60.86
Upside: +38.02%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,025.00
Upside: -48.78%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $4.45
Upside: +192.13%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $10.47
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $117.15
Upside: -20.61%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $26.88
Upside: +78.57%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $2.11
Upside: +1,132.23%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.64
Upside: +23,484.91%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $14.39
Upside: +442.04%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $128.13
Upside: -39.12%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $34.37
Upside: -47.63%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $187.02
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $165.63
Upside: +5.66%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $222.44
Upside: -70.33%